Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|LMD
Interventions: DRUG: Tucatinib 150 MG|DRUG: Trastuzumab|DRUG: Capecitabine|RADIATION: Brain & Spinal Radiation
Sponsor: Sunnybrook Health Sciences Centre
Collaborators: Seagen Inc.|Biocon Biologics